Thomas Bschleipfer

ORCID: 0000-0003-4008-4598
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Urinary Bladder and Prostate Research
  • Pelvic floor disorders treatments
  • Urological Disorders and Treatments
  • Prostate Cancer Diagnosis and Treatment
  • Urinary Tract Infections Management
  • Sexual function and dysfunction studies
  • Hormonal and reproductive studies
  • Genital Health and Disease
  • Urologic and reproductive health conditions
  • Kidney Stones and Urolithiasis Treatments
  • Pediatric Urology and Nephrology Studies
  • Abdominal Trauma and Injuries
  • Neuropeptides and Animal Physiology
  • Plant Toxicity and Pharmacological Properties
  • Neuroendocrine regulation and behavior
  • Diverticular Disease and Complications
  • Pelvic and Acetabular Injuries
  • Biochemical Analysis and Sensing Techniques
  • Anorectal Disease Treatments and Outcomes
  • Olfactory and Sensory Function Studies
  • Minimally Invasive Surgical Techniques
  • Thermoregulation and physiological responses
  • Medical and Health Sciences Research
  • Nicotinic Acetylcholine Receptors Study
  • Sympathectomy and Hyperhidrosis Treatments

Klinikum Coburg
2022-2025

L-3 Communications (United States)
2024

Klinikum Weiden
2015-2022

Justus-Liebig-Universität Gießen
2005-2015

Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie
2005-2014

Universitätsklinikum Gießen und Marburg
2011-2014

Ludwig-Maximilians-Universität München
2014

Leipzig University
2009

Technical University of Munich
2009

University Hospital of Zurich
2004

Chemosensory cells in the mucosal surface of respiratory tract ("brush cells") use canonical taste transduction cascade to detect potentially hazardous content and trigger local protective aversive reflexes on stimulation. So far, urogenital has been considered lack this cell type. Here we report presence a previously unidentified cholinergic, polymodal chemosensory mammalian urethra, potential portal entry for bacteria harmful substances into system, but not further centrally located parts...

10.1073/pnas.1402436111 article EN Proceedings of the National Academy of Sciences 2014-05-19

Das benigne Prostatasyndrom (BPS) ist die häufigste Erkrankung des unteren Harntrakts beim Mann und kann großen Einfluss auf Lebensqualität der Betroffenen nehmen. Instrumentelle Therapien sind häufig, viele Patienten streben mittlerweile eine operative Therapie mit weniger Morbidität als bei den klassischen Prostataoperationen an. Es handelt sich um Darstellung evidenzbasierte Bewertung minimalinvasiven (MIT) BPS. Der Artikel liefert Zusammenfassung Übersicht Kapitel 11–13 zur MIT BPS...

10.1007/s00120-023-02249-4 article DE Deleted Journal 2024-01-01

Extracorporeal shock wave therapy (ESWT) for Peyronie's disease is still a topic of debate. We evaluated the effects ESWT in large series patients with via prospective approach.In study 114 were treated ESWT. Baseline and followup examinations included ultrasound, measurement plaque size curvature. Symptomatology was based on standardized interview. A Minilith SL1 (Storz Medical AG, Kreuzlingen, Switzerland) lithotriptor used 4,000 waves at maximum energy level 0.17 mJ/mm2 applied per...

10.1097/01.ju.0000099891.68488.4e article EN The Journal of Urology 2004-01-01

Benign prostatic hyperplasia (BPH) is the most common disease of lower urinary tract in men. The prevalence increases continuously with increasing age and a chronic progressive course to be expected. In order reduce morbidity affected patients improve their quality life, expert panel Prostatic Hyperplasia German Society Urology (DGU) has written new version evidence-based "S2e guideline on diagnosis treatment BPH". Using current patient case, contents S2e are illustrated, from...

10.1007/s00120-024-02327-1 article EN Deleted Journal 2024-04-10

Importance Studies with nivolumab, an approved therapy for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy, demonstrate improved outcomes added high-dose ipilimumab. Objective To assess efficacy and safety of a tailored approach using nivolumab + ipilimumab as immunotherapeutic boost mUC. Design, Setting, Participants In this phase 2 nonrandomized trial, patients mUC composed cohorts. Cohort 1 received first-line or second-/third-line escalating doses ipilimumab,...

10.1001/jamaoncol.2024.0938 article EN JAMA Oncology 2024-05-09

The prevalence of systemic atherosclerosis and overactive bladder/detrusor overactivity increases almost simultaneously with age but an association between these diseases has not yet been proved. We evaluated changes in bladder function morphology, including vascularization, apoE(-/-)LDLR(-/-) double knockout mice without central nervous system involvement.Cystometry was performed awake, freely moving 60-week-old C57BL/6N controls. were sacrificed perfused Microfil® contrast medium. excised,...

10.1016/j.juro.2014.08.098 article EN The Journal of Urology 2014-08-27

<b><i>Introduction:</i></b> To evaluate therapeutic results till 5 years after therapy of obstructive pyelonephritis (OPN) emphasizing regular follow-up. <b><i>Material and Methods:</i></b> During years, 57 patients with OPN were treated. The patients' charts reviewed retrospectively for clinical data. These completed by a questionnaire. <b><i>Results:</i></b> In the group (average age 56 years), about two third women....

10.1159/000368051 article EN Urologia Internationalis 2015-01-01
Coming Soon ...